US Can Improve Ovarian Cancer Diagnosis
An algorithm for the assessment of adnexal masses with ultrasound allows quantification of the risk of malignancy, according to work published in the American Journal of Obstetrics and Gynecology. The method, based on the “Simple Rules” criteria developed by the International Ovarian Tumor Analysis (IOTA) group, identified between 89-99% of patients with ovarian cancer. As ultrasound is widely available, this promises improved diagnosis.
The IOTA group’s study, led by Professor Dirk Timmerman, MD, PhD, of the Department of Obstetrics and Gynecology, University Hospitals Leuven, Belgium, validates this model to predict the risk of malignancy in adnexal masses, and represents the culmination of studies involving approximately 5,000 patients with adnexal masses.
The investigators examined patients prior to surgery with a standardised examination technique and standardised terms and definitions to describe ultrasound findings. The predictions were compared with the histological findings and the risk of malignancy was calculated.
See Also: Robots Raise Adnexal Surgery Costs, Complications
Prof. Timmerman noted that the risk estimates derived from the 5 US features in the Simple Rules perform similarly to the best algorithms previously published. He suggested: "A simple classification based on these risk estimates may form the basis of a clinical management approach. This will hopefully facilitate choosing optimal treatment for all patients presenting with adnexal masses."
Beryl Benacerraf, MD, President of the American Institute of Ultrasound in Medicine (AIUM) and Clinical Professor of Radiology and OB GYN at Brigham and Women's Hospital, Harvard Medical School, Boston, commented in an editorial: “I applaud this group for grappling with the challenging problem of the variability of ultrasound diagnoses of adnexal masses depending on the expertise of acquisition and interpretation, and succeeding in developing a simple, standardized, and scalable solution. By at once leveling and elevating the playing field, application of this method places expert interpretation and improved diagnostic ability within reach of all practitioners."
Source: American Journal of Obstetrics and Gynecology, Elsevier Health Sciences
Benacerraf B Ultrasonic diagnosis of ovarian masses: Can the playing field be leveled and raised at the same time?(2016), DOI: http://dx.doi.org/10.1016/j.ajog.2015.12.045.
Published online in advance of Volume 214, Issue 4 (April 2016) of the American Journal of Obstetrics and Gynecology.
Published on : Tue, 19 Jan 2016
We recognize that the best chance any patient has at getting better is a clinician at their bedside with all the right answers and the confidence to act. SonoSite education and training is the industry standard – no other point-of-care ultrasound manufacturer...
The iViz is a lightweight Point Of Care (POC) ultrasound solution, specifically designed for emerging sub-segments where there is need for a highly accessible and mobile solution that is capable throughout key areas of the patient care path. The iViz...
Open high-field efficiency with patient-centric architecture OASIS™ is a new generation of MR systems, providing a high degree of diagnostic confidence and extraordinary patient comfort. With this unique scanner, Hitachi combines best high-field performance...
The SonoSite EDGE II is a high-resolution, all-digital, 9.0-pound (4.1 kg) ultrasound system with a 12.1in. LED full-bleed glass display. The Edge II boosts improvements in cardiac and abdominal image quality through DirectClear Technology and a new...
BioZorb® 3D Bioabsorbable Marker The BioZorb® is a 3D implantable marker that consists of a spiral, bioabsorbable framework embedded with 6 permanent, titanium clips designed to precisely mark your surgical excision site. Designed to improve outcomes...